EP2188285A1 - Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha - Google Patents

Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha

Info

Publication number
EP2188285A1
EP2188285A1 EP08787154A EP08787154A EP2188285A1 EP 2188285 A1 EP2188285 A1 EP 2188285A1 EP 08787154 A EP08787154 A EP 08787154A EP 08787154 A EP08787154 A EP 08787154A EP 2188285 A1 EP2188285 A1 EP 2188285A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkoxy
alkylamino
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08787154A
Other languages
German (de)
English (en)
Inventor
Samuel Hintermann
Konstanze Hurth
Joachim Nozulak
Marina Tintelnot-Blomley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to EP08787154A priority Critical patent/EP2188285A1/fr
Publication of EP2188285A1 publication Critical patent/EP2188285A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Definitions

  • the present invention relates to heterocyclic compounds, to their preparation, to their use as medicaments and to medicaments comprising them.
  • the invention relates to a compound of the formula I
  • R 3 represents an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted heterocyclyl group; a substituted alkyl group and m represents O, 1 , 2 or 3; or
  • R 3 represents hydrogen and m represents 2, 3, 4, 5 or 6;
  • R 5 represents hydrogen or alkyl
  • Y represents O or S
  • R 1 represents an optionally substituted aryl group, an optionally substituted cycloalkyl group or an optionally substituted alkyl group
  • X 1 represents N, CR 4
  • X 2 represents N, CR 4
  • X 3 represents N, CR 4
  • X 4 represents N, CR 4 ;
  • R 4 represents hydrogen or a substituent different from hydrogen; R 2 represents hydrogen or a substituent different from hydrogen; and provided that not more than two of X 1 - X 4 represent nitrogen; in free base form or in acid addition salt form. If at least one asymmetrical carbon atom is present in a compound of the formula I, such a compound may exist in optically active form or in the form of a mixture of optical isomers, e. g. in the form of a racemic mixture. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention.
  • the acid addition salt of compounds of formula I are preferably pharmaceutically acceptable salts. Such salts are known in the field.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable.
  • the present invention includes all pharmaceutically acceptable isotopically-labeled compounds of the invention, i.e. compounds of formula (I), wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention comprises isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 CI, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 0, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • hydrogen such as 2 H and 3 H
  • carbon such as 11 C, 13 C and 14 C
  • chlorine such as 36 CI
  • fluorine such as 18 F
  • iodine such as 123 I and 125 I
  • nitrogen such as 13 N and 15 N
  • oxygen such as 15 0, 17 O and 18 O
  • phosphorus such as 32 P
  • sulphur such as 35 S.
  • isotopically-labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in - A -
  • each substituent may be independently selected from the list of possible substituents, i.e. one R4 may be hydrogen, other substituents R4 may be hydrogen or different from hydrogen.
  • Halogen denotes fluorine, bromine, chlorine or iodine.
  • Aryl is preferably naphthyl or phenyl, in particular phenyl.
  • Heterocyclyl represents a saturated or partly saturated ring system containing at least one hetero atom.
  • heterocyclyl groups consist of 3 to 1 1 ring atoms of which 1 -3 ring atoms are hetero atoms.
  • Heterocycles may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring system or as benz-annelated ring system.
  • Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings, by a bridging atom, e.g. Oxygen, sulfur, nitrogen or by a bridging group, e.g. alkandediyl or alkenediyl.
  • Heteroaryl represents an aromatic ring system containing at least one hetero atom.
  • heteroaryl groups consist of 3 to 1 1 ring atoms of which 1 -3 ring atoms are hetero atoms.
  • Heteroary groups may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring system or as benz-annelated ring system. Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings.
  • heterocyclyl and heteroaryl groups include: pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane, dihydrofurane, tetrahydrofurane, furazane (oxadiazole), dioxolane, thiophene, dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine, isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline, thiazlolidine, isothiazole, istothiazoline, isothiazolidine, thiadiazole, thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine, pyridine
  • Arylalkyl represents an aryl group bound to the molecule via an alkyl group, such as a methyl or ethyl group, preferably phenethyl or benzyl, in particular benzyl.
  • cycloalkylalkyl and heterocyclyl represents a cycloalkyl group bound to the molecule via an alkyl group or a heterocyclyl group bound to the molecule via an alkyl group.
  • Carbon containing groups, moieties or molecules contain 1 to 8, preferably 1 to 6, more preferably 1 to 4, most preferably 1 or 2, carbon atoms. Any non-cyclic carbon containing group or moiety with more than 1 carbon atom is straight-chain or branched.
  • Hetero atoms are atoms other than Carbon and Hydrogen, preferably nitrogen (N), oxygen (O) or sulfur (S).
  • Halogen-substituted groups and moieties such as alkyl substituted by halogen (halogenalkyl) can be mono-, poly- or per-halogenated.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, wherein the substituents are as defined below.
  • R 1 preferably represents an optionally mono-, di-, tri- or tetra-substituted aryl group, an optionally mono-, di-, tri- or tetra-substituted cycloalkyl group or an optionally mono-, di- , tri- or tetra-substituted alkyl group; the substituent(s) being independently selected from the group consisting of halogen, (d- 8 )alkyl, (d- 8 )alkyl substituted by halogen, (C 3 - 8)cycloalkyl, (C 3 - 8 )cycloalkyl(Ci- 8 )alkyl, (C 3 . 8 )cycloalkoxy, (C 3 .
  • R 1 particular preferably represents an unsubstituted or mono-, di-, tri- or tetra-substituted aryl group, a unsubstituted or mono-, di-, tri- or tetra-substituted (C 3 - 8 )cycloalkyl group or an unsubstituted, mono-, di-, tri- or tetra-substituted (C 1-8 )alkyl group, the optional substituent(s) being independently selected from the group, consisting of halogen, (Ci_ 8)alkyl, hydroxy, (Ci -8 )alkoxy, (Ci- 8 )alkoxy substituted by halogen, amino(Ci- 8 )alkoxy, (Ci- 8 )alkylamino(Ci- 8 )alkoxy, di(Ci- 8 )alkylamino(Ci- 8 )alkoxy with two identical or different (Ci -8 )alkyl
  • R 1 very particular preferably represents a phenyl substituted by one or two substituents selected from the group consisting of halo, cyano, CrC 4 alkoxy, such as fluoro, chloro, cyano, methoxy.
  • R 1 further very particular preferably represents unsubstituted (Ci -8 )alkyl or unsubstituted (C 3 - 8 )cycloalkyl.
  • R 2 is preferably selected from the group consisting of hydrogen, halogen, (d- 8 )alkyl, (Ci- 8 )alkyl substituted by halogen, (C 3-8 )cycloalkyl, (C 3-8 )cycloalkyl(Ci -8 )alkyl, (C 3 . 8)cycloalkoxy, (C 3-8 )cycloalkoxy(Ci- 8 )alkyl, (C 3 .
  • R 2 particular preferably represents hydrogen or (d- 4 )alkyl.
  • R 2 very particular preferably represents hydrogen.
  • R 3 preferably represents an aryl group or a (C 3 -C 8 )cycloalkyl group or a heterocyclyl group with 3 to 8 ring atoms or a heteroaryl group with 3 to 8 ring atoms or a (Ci-C 8 )alkyl group; wherein said aryl group, (C 3 -C 8 )cycloalkyl group, heteroaryl group, heterocyclyl group group is unsubstituted, mono-substituted, di-substituted or tetra- substituted, the optional substituent(s) being independently selected from the group consisting of halogen, (C 1 -8 )alkyl, (C 1 -8 )alkyl substituted by halogen, (C 3 .
  • R 3 particular preferably represents an aryl group or a (C 3 -C 8 )cycloalkyl group or a heteroaryl group with 5 or 6 ring atoms, or a heterocyclyl group with 5 or 6 ring atoms, which is unsubstituted or mono-, di-, tri- or tetra-substituted on the aryl group, the optional substituent(s) on said moiety being independently selected from the group, consisting of halogen, cyano, (Ci -8 )alkyl, (Ci -8 )alkyl substituted by halogen, nitro, (Ci-s)alkoxy, (Ci_ 8 )alkoxy substituted by halogen, (Ci -8 )alkylthio, formyloxy, (Ci -8 )alkylcarbonyloxy; which is unsubstituted or mono-, di-, tri- or tetra-substituted on the (C 3 -
  • R 3 (CHR 5 ) m - further preferably represents ethyl, n-, iso-propyl, n-, iso-, sec.-, tert. -butyl, n-, sec.-neo.-, iso-pentyl, n-, iso-, sec.-hexyl.
  • Each R 4 is independently and preferably selected from the group consisting of hydrogen, halogen, (C 1 -8 )alkyl, (C 1 -8 )alkyl substituted by halogen, (C 3 . 8 )cycloalkyl, (C 3 . 8 )cyclo- alkyl(Ci- 8 )alkyl, (C 3 . 8 )cycloalkoxy, (C 3 - 8 )cycloalkoxy(Ci- 8 )alkyl, (C 3 .
  • Each R 4 is independently and particular preferably selected from the group consisting of hydrogen, halogen, cyano, (d- 8 )alkyl, (Ci -8 )alkyl substituted by halogen, (Ci -8 )alkoxy, amino, (Ci -8 )alkylamino and di(C 1 . 8 )alkylamino with two identical or different (Ci -8 )alkyl moieties;
  • Each R 4 is further independently and particular preferably selected from the group consisting of imidazol, pyrazol, triazol, pyridine, pyrazine, pyrimidin, pyridazin, each optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, (Ci -8 )alkyl, (Ci -8 )alkyl substituted by halogen.
  • Each R 4 is independently and very particular preferably selected from the group consisting of hydrogen, fluoro, chloro, cyano, (d- 4 )alkyl, (d- 4 )alkyl substituted by fluoro.
  • R 5 preferably represents hydrogen or (d- 4 )alkyl.
  • R 5 particular preferably represents hydrogen or methyl.
  • Y preferably represents O.
  • n preferably represents O, 1 or 2 if R 3 is a substituent as defined above other than hydrogen.
  • n particular preferably represents 1 if R 3 is a substituent as defined above other than hydrogen.
  • Each of X 1 to X 4 preferably represents CR 4 .
  • the invention relates to a compound of formula IA
  • the invention relates to a compound of formula IB
  • R 1 represents a phenyl substituted in the ortho and/or para-position(s) or in the para position.
  • the invention relates to one or more than one of the compounds of the formula I mentioned in the Examples hereinafter, in free base form or in acid addition salt form.
  • the invention relates to a process for the preparation of the compounds of the formula I and their salts, comprising the steps of
  • substituents are as defined for the formula I, optionally in the presence of a base, such as a hydride; optionally in the presence of one or more diluents; or
  • substituents are as defined for the formula I, with POCI 3 followed by a reaction with a compound of the formula III wherein the substituents are as defined for the formula I, optionally in the presence of a base, such as a hydride; optionally in the presence of one or more diluents; and optionally followed by reduction, oxidation or functionalization reaction of the resulting compound of formula I and/or by cleavage of protecting groups optionally present, and optionally followed by recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.
  • a base such as a hydride
  • one or more diluents optionally followed by reduction, oxidation or functionalization reaction of the resulting compound of formula I and/or by cleavage of protecting groups optionally present, and optionally followed by recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.
  • the reactions can be effected according to conventional methods, for example as described in the Examples.
  • the working-up of the reaction mixtures and the purification of the compounds thus obtainable may be carried out in accordance with known procedures.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • the starting materials of the formulae II, III and IV are known or may be prepared according to conventional procedures starting from known compounds, for example as described in the Examples.
  • Agents of the invention exhibit valuable pharmacological properties, when tested in vitro and in animals, and are, therefore, useful as active ingredients in medicaments.
  • Agents of the invention have good efficacy as selective ligands for GABA-A receptors, showing desirable GABA-A receptor modulating activities at various receptor subtypes, and, moreover, may possess interesting pharmacokinetic properties, e. g. improved oral bioavailability or enhanced metabolic stability.
  • GABA-A receptors which are members of the ligand-gated ion channel superfamily
  • GABA-B receptors which are members of the G-protein coupled receptors superfamily. Since the first cloning of cDNAs encoding individual GABA-A receptor subunits, the number of known mammalian subunits has grown to include at least six alpha subunits, three beta subunits, three gamma subunits, three rho subunits, one delta, one epsilon, one pi, and one phi subunits.
  • rho subunits which form homomultimeric receptor channels formerly known as GABA-C receptors
  • GABA-C receptors a pentameric assembly of either alpha and beta subunits or alpha, beta and gamma subunits constitute the minimum requirement for forming a fully functional GABA-A receptor, when expressed by transiently transfecting cDNAs into cells.
  • Functional receptor subtype assemblies which do exist, include alpha1 beta2gamma2, alpha2beta2gamma2 or alpha2beta3gamma2 (alpha2beta2/3gamma2), alpha3beta2/3gamma2 and alpha5beta2gamma2.
  • Delta, epsilon, pi and phi subunits are present only to a minor extent in GABA-A receptor populations.
  • Subtype assemblies containing an alphal subunit are present in most areas of the brain and are thought to account for over 40% of GABA-A receptors in the rat.
  • Subtype assemblies containing alpha2 or alpha3 subunits, respectively are thought to account for about 25% or 17%, respectively, of GABA-A receptors in the rat.
  • Subtype assemblies containing alpha ⁇ subunits are expressed predominantly in the hippocampus and the cortex.
  • a characteristic property of all known GABA-A receptors is the presence of a number of modulatory sites.
  • BZD benzodiazepine
  • the alphal -selective GABA-A receptor modulators Zolpidem and alpidem are clinically prescribed as hypnotic agents, suggesting that the sedation associated with known anxiolytic drugs, which act at the BZD binding site, is mediated through GABA-A receptors containing the alphal subunit.
  • Compounds with inhibitory activity at the BZD site of alpha5beta2gamma2 receptor subtypes are believed to have memory improving effects.
  • GABA-A receptor modulators show in functional assays a positive modulation of GABA- induced signals. This modulation can be determined in vitro, e. g., at recombinant GABA-A receptors expressed in a mammalian cell line, e. g. by measurement of GABA-A receptor induced changes of the trans-membrane voltage, when using a voltage-sensitive dye and a fluorescence detection system (Adkins, C. E., Pillai, G. V., Kerby, J., Bonnert, T.P., Haldon, C, Mckernan, R. M., Gonzalez, J. E., Oades, K., Whiting, PJ. & Simpson, P. B. [2001].
  • alpha4beta3delta GABA-A receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential. J. Biol. Chem., 276, 38934-38939).
  • a modulator compound is pre-applied at different concentrations ranging from 0.1 nM to 10 ⁇ M to cells expressing GABA-A receptors and loaded with the voltage-sensitive dye, before, or at the same time as, a sub-maximal concentration of GABA (in the range of from 0.1 to 10 ⁇ M) is applied to the cells.
  • the fluorescent signal is correlated with the degree of GABA-A receptor channel opening. This allows the quantification of effects induced by the modulator in a functional manner.
  • GABA-A receptor subunit combinations By expression of different GABA-A receptor subunit combinations, the differential efficacy of a modulator at different GABA-A receptor variants can be tested.
  • Other functional assays include the electrophysiological recording of Xenopus oocytes or mammalian cells expressing respective receptor variants.
  • ion flux detectors can be used to functionally study GABA-A receptors in heterologous expression systems.
  • the affinity of a compound to the GABA-A receptor can be measured in radioligand binding experiments using reference ligands containing a radioactive element, e. g., tritiated flumazenil, and intact cells or membrane preparations of cells expressing GABA-A receptors.
  • Activity and selectivity of a GABA-A receptor modulator according to the invention can, e. g., be determined in vitro as follows: A transfected eukaryotic cell line expressing the alphal , alpha2 or alpha3 subunit of the GABA-A receptor together with a beta and a gamma subunit of the GABA-A receptor is incubated with a voltage-sensitive dye, and the effects of an agonist (typically GABA) or modulator addition are recorded in a fluorimetric plate reader. The opening of the GABA-A receptor channel and the subsequent flux of anions through it changes the trans-membrane voltage of the transfected cells, leading to a change in the fluorescent signal of the voltage-sensitive dye.
  • a sub-maximal concentration of GABA e. g. an EC 2 O or an EC 50
  • GABA e. g. an EC 2 O or an EC 50
  • agents of the invention modulate the GABA-induced response at concentration from about 0.1 to about 10'0OO nM.
  • a GABA-A receptor modulator can be tested in a variety of behavioral or biochemical assays, including, e. g., tests, that assess the anxiolytic-like properties, like the stress- induced hyperthermia test, the light-dark-box assay, the punished drinking (or Vogel-conflict) test, the elevated maze tests or the fear-potentiated startle response test, or tests, that assess the sedative or motor-impairing properties, like the rotarod assays, the test de traction, the primary observation test or the horizontal and vertical locomotion tests.
  • tests that assess the anxiolytic-like properties, like the stress- induced hyperthermia test, the light-dark-box assay, the punished drinking (or Vogel-conflict) test, the elevated maze tests or the fear-potentiated startle response test, or tests, that assess the sedative or motor-impairing properties, like the rotarod assays, the test de traction, the primary observation test or
  • agents of the invention are useful in the treatment or prevention of a variety of disabilitating psychiatric, psychotic or neurological states, e. g. of conditions, disorders or diseases of the nervous system, that can be modulated or are mediated, fully or in part, by GABA-A receptors.
  • Such conditions, disorders or diseases include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal or other specific phobias, including social phobias, social anxiety disorder, anxiety, obsessive-compulsive disorder, stress disorders, including post-traumatic or acute stress disorder, or generalized or substance- induced anxiety disorders; neuroses; seizures; epilepsy, especially partial seizures, simple, complex or partial seizures evolving to secondarily generalized seizures or generalized seizures [absence (typical or atypical), myoclonic, clonic, tonic, tonic-clonic or atonic seizures]; convulsions; migraine; affective disorders, including depressive or bipolar disorders, e. g.
  • psychotic disorders including schizophrenia; neurodegeneration arising from cerebral ischemia; acute, traumatic or chronic degenerative processes of the nervous system, such as Parkinson's disease, Down's syndrome, senile dementia, cognitive disorders, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis or fragile X syndrome; attention disorders, e. g. attention deficit hyperactivity disorder; Tourette's syndrome; speech disorders, including stuttering; disorders of the circadian rhythm, e. g.
  • Agents of the invention may also be useful in enhancing cognition, e. g.
  • the appropriate dosage will vary depending on, e. g., the compound employed, the host, the mode of administration and the nature and severity of the condition, disorder or disease. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100, preferably from about 1 to about 50, mg/kg of animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range of from about 10 to about 2000, preferably from about 10 to about 200, mg of an agent of the invention conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
  • An agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
  • the invention in a further aspect, relates to an agent of the invention, for use as a medicament, e. g. for the treatment or prevention of conditions, disorders or diseases, that can be modulated or are mediated by GABA-A receptors.
  • the invention relates to the use of an agent of the invention as active ingredient in a medicament, e. g. for the treatment or prevention of conditions, disorders or diseases, that can be modulated or are mediated by GABA-A receptors.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an agent of the invention as active ingredient in association with at least one pharmaceutical carrier or diluent.
  • Such compositions may be manufactured in conventional manner.
  • Unit dosage forms contain, for example, from about 1 to about 1000, preferably from about 1 to about 500, mg of an agent of the invention.
  • the agents of the invention can be administered alone or as combination with other pharmaceutical agents effective, e. g., in the treatment or prevention of conditions, disorders or diseases mentioned above.
  • Such pharmaceutical combinations may be in the form of a unit dosage form, whereby each unit dosage will comprise a predetermined amount of the two components in admixture with at least one pharmaceutical carrier or diluent.
  • the combination may be in the form of a package containing the two components separately, e. g. a pack or dispenser-device adapted for the concomitant or separate administration of the two active agents, wherein these agents are separately arranged.
  • the invention relates to such pharmaceutical combinations.
  • the invention relates to the use of an agent of the invention for the manufacture of a medicament for the treatment or prevention of conditions, disorders or diseases, that can be modulated or are mediated by GABA-A receptors.
  • the invention relates to a method for the treatment or prevention of conditions, disorders or diseases, that can be modulated or are mediated by GABA-A receptors, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
  • Agilent 1 100 series LC pump Agilent 1 100 series DAD; Agilent 1 100 series CoI Oven; CTC PAL autosampler; Waters ZQ2000 MS; column Waters XTerra C18 2.5 ⁇ m; 3 x 30 mm; 50 °C; mobile phase: A water 95% + acetonitrile 5% + formic acid 0.2% / B acetonitrile 100% + formic acid 0.2%; injection volume 5 ⁇ l; flow 600 ⁇ l/min; gradient 5 - 95% B in 3.5 min; MS parameter 100 - 900 Da; ESI+ cone 17V.
  • Agilent 1 100 series LC pump Agilent 1 100 series DAD; Agilent 1 100 series CoI Oven; CTC PAL autosampler; Waters ZQ2000 MS; column Waters XTerra C18 2.5 ⁇ m; 3 x 30 mm; 50 °C; mobile phase: A water 95% + acetonitrile 5% + formic acid 0.2% / B acetonitrile 100% + formic acid 0.2%; injection volume 5 ⁇ l; flow 600 ⁇ l/min; gradient 1 - 95% B in 3.5 min; MS parameter 100 - 900 Da; ESI+ cone 17V.
  • Agilent 1 100 series LC pump Agilent 1 100 series DAD; Agilent 1 100 series CoI Oven; CTC PAL autosampler; Waters ZQ2000 MS; column Waters XTerra C18 2.5 ⁇ m; 3 x 30 mm; 50 9 C; mobile phase: A water 95% + acetonitrile 5% + formic acid 0.2% / B acetonitrile 100% + formic acid 0.2%; injection volume 5 ⁇ l; flow 600 ⁇ l/min; gradient 10 - 95% B in 1 .5min; MS parameter 100 - 900 Da; ESI+ cone 27V.
  • 2-Phenylaminomethylene-malonic acid diethyl ester 2-(Ethoxymethylene)-malonic acid diethyl ester (50 mmol) and aniline (50 mmol) are mixed in a flask. The flask is sealed, and the mixture is heated to 150 9 C in a microwave reactor, stirred for 15 min and then cooled to rt. The crude oil is purified by flash-chromatography (cyclohexane / EtOAc 90 : 10) to yield the title compound in the form of a yellow, viscous oil.
  • 4-Chloro-quinoline-3-carboxylic acid ethyl ester 4-Hydroxy-quinoline-3-carboxylic acid ethyl ester (2.53 mmol) and 4.5 ml of POCI 3 are mixed in a flask. The flask is sealed, and the mixture is heated to 135°C, stirred for 30 min, then cooled to rt and poured onto water. The mixture is stirred for 10 min, then cooled with an ice bath, basified with aqueous NaOH solution to pH 1 1 - 12 and extracted with DCM (3 times). The combined organic fractions are dried (sodium sulfate), filtered and evaporated. The residue is purified by flash- chromatography (cyclohexane / EtOAc 60 : 40) to yield the title compound in the form of a light yellow solid.
  • 2-(4-methoxy-phenyl)-1 ,2-dihydro-pyrazolo[4,3-c]quinolin-3-one To 1 ml of EtOH, 4-chloro- quinoline-3-carboxylic acid ethyl ester (1 .00 mmol), (4-methoxyphenyl)-hydrazine (1.05 mmol) and 350 ⁇ l of triethylamine are added. The mixture is stirred in a sealed flask in a microwave reactor for 10 min at 150 9 C and then for 10 min at 120 9 C. Then, further (4- methoxyphenyl)-hydrazine (0.5 mmol) is added.
  • agents of the invention as GABA-A alpha2 and/or alphal receptor modulators is tested as described above (fluorescence measurements of transfected eukaryotic cell lines expressing the alpha 1 or 2 subunit together with a beta and a gamma subunit). The compounds are tested at 3 ⁇ M and at a sub-maximal concentration of GABA (EC 2 o). The values are expressed as "%mod" meaning a percentage of increase of the fluorescent signal compared to the fluorescent signal obtained without the agent of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur un composé représenté par la formule I Y R3 R5 m X1 X2 X3 X4 NN N R1 R2 (I) dans laquelle les substituants sont tels que définis dans la description; sous une forme de base libre ou sous forme de sel d'addition avec les acides; sur sa préparation, sur son utilisation comme médicament et sur des médicaments le comprenant.
EP08787154A 2007-08-14 2008-08-12 Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha Withdrawn EP2188285A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08787154A EP2188285A1 (fr) 2007-08-14 2008-08-12 Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07114340 2007-08-14
PCT/EP2008/060603 WO2009021961A1 (fr) 2007-08-14 2008-08-12 Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha
EP08787154A EP2188285A1 (fr) 2007-08-14 2008-08-12 Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha

Publications (1)

Publication Number Publication Date
EP2188285A1 true EP2188285A1 (fr) 2010-05-26

Family

ID=38787627

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08787154A Withdrawn EP2188285A1 (fr) 2007-08-14 2008-08-12 Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha

Country Status (5)

Country Link
US (1) US20110294799A1 (fr)
EP (1) EP2188285A1 (fr)
JP (1) JP2010535844A (fr)
CN (1) CN101784547A (fr)
WO (1) WO2009021961A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011301518B2 (en) * 2010-09-16 2014-07-03 Hutchison Medipharma Limited Fused heteroaryls and their uses
CN103124731B (zh) * 2010-09-16 2016-01-20 和记黄埔医药（上海）有限公司 稠合的杂芳基化合物及其应用
CN102977095B (zh) * 2012-12-03 2015-10-28 华东理工大学 吡唑并喹啉类化合物及其用途
CN114213412B (zh) * 2022-01-28 2022-12-30 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种酸催化2-吡唑苯胺衍生物与醚合成吡唑并喹啉化合物的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713707D0 (en) * 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
GB9716345D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
CN100572381C (zh) * 2002-11-06 2009-12-23 Aska制药株式会社 吡唑并二氮杂萘衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009021961A1 *

Also Published As

Publication number Publication date
WO2009021961A1 (fr) 2009-02-19
JP2010535844A (ja) 2010-11-25
CN101784547A (zh) 2010-07-21
US20110294799A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
KR100883003B1 (ko) 알츠하이머병의 치료를 위한 글라이신 수송체1(ｇｌｙｔ-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온
US20090215746A1 (en) Substituted pyrazolo[1,5-a]pyrimidines as calcium receptor modulating agents
JP5972964B2 (ja) 抗腫瘍剤としての三環式および四環式ピラゾロ［３，４−ｂ］ピリジン化合物
MXPA05011454A (es) Ligandos de receptores de canabinoides y sus usos.
JP6111268B2 (ja) Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
TW201206944A (en) Morpholine compounds
CA2870062A1 (fr) Inhibiteurs de tankyrase de type pyrrolopyrazone
AU2013329097B2 (en) Urea and amide derivatives of aminoalkylpiperazines and use thereof
CA2932175A1 (fr) Inhibiteurs d'itk et de jak3 3,5-(non)substitue-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine et 5h-pyrrolo[2-,3-b]pyrazine
KR101889694B1 (ko) Ｓ１ｐ 조절제로서의 융합된 헤테로사이클릭 유도체
AU1719901A (en) Pyrazolo-pyridine derivatives as ligands for gaba receptors
CA3056355A1 (fr) Derives heterocycliques destines au traitement de la fibrose kystique
CA3210332A1 (fr) Inhibiteurs de prmt5 tricycliques-amido-bicycliques
PH12016502293B1 (en) Naphthyridinedione derivatives
US20030073717A1 (en) Triazolo-pyridine derivatives as ligands for GABA receptors
EP2188285A1 (fr) Dérivés de pyrazoloquinoléine et de pyrazolonaphtyridine comme ligands gaba alpha
CN114149424A (zh) 用于治疗疾病的杂环化合物
JP2010520255A (ja) ｍＧｌｕＲリガンドとしての縮合ピリミジノン化合物
WO2009021957A2 (fr) Composés organiques
US20240124455A1 (en) Tricyclic compounds as anticancer agents
WO2018080918A1 (fr) Composés 3-aryl-2h-pyrazolo[4,3-b]pyridine et leur utilisation en tant que modulateurs du récepteur ampa
PL100372B1 (pl) Sposob wytwarzania nowych 1-/alfa-fenylo-o-tolilo/-imidazoli albo 2-/imidazolilo-1/-benzofenonow
US9012470B2 (en) Therapeutic 5,6,5-tricyclic analogs
JP2024072283A (ja) Ａｈｒアゴニスト

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100906

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110118